The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback